
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics Inc. is actively advancing its lead product, deramiocel, through Phase 3 clinical development for Duchenne muscular dystrophy, supported by a successful partnership that enhances its operational runway and positions the company for future commercialization efforts in Europe. The therapeutic has demonstrated a favorable long-term benefit-risk profile without new safety concerns, signaling strong potential for market acceptance and efficacy. Positive developments in regulatory discussions further mitigate risks, enhancing the overall outlook for Capricor’s share value as investors respond to encouraging milestones in deramiocel's pathway.
Bears say
Capricor Therapeutics Inc's recent clinical data for deramiocel indicates a modest reduction in disease progression, yet the observed mean annual decline in Performance of the Upper Limb 2.0 (PUL 2.0) scores raises concerns about the efficacy of the treatment, with differences in performance highlighting the potential for inconclusive trial results. The company faces significant challenges in securing sufficient funding to advance its drug development, which adds uncertainty to its financial stability and prospects for advancing its lead products. Additionally, the risk of failing or inconclusive clinical trials could severely hinder Capricor's ability to achieve its strategic objectives and adversely impact investor confidence in the stock.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares